Combination immunosuppressant and immunomodulator

This page covers all Combination immunosuppressant and immunomodulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Glucocorticoid receptor (methylprednisolone); Fc receptors and complement (IVIG).

Targets

Glucocorticoid receptor (methylprednisolone); Fc receptors and complement (IVIG)

Phase 3 pipeline (1)

• Methylprednisolone and IVIG · The Hospital for Sick Children · Immunology
  Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways.

Patent intelligence

• combination immunosuppressant and immunomodulator patent landscape — aggregated cliff calendar, attackable patents, originator estates